Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - levofloxacin hemihydrate - film coated tablet - 500 milligram - fluoroquinolones

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - levofloxacin - solution for infusion - levofloxacin 5 mg/ml - antibacterials for systemic use

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - levofloxacin - film-coated tablet - levofloxacin 250 mg - antibacterials for systemic use

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - levofloxacin - film-coated tablet - levofloxacin 500 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - levofloxacin hemihydrate - film-coated tablet - 250 milligram(s) - fluoroquinolones; levofloxacin - pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones, - it is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): - acute bacterial sinusitis. - acute exacerbations of chronic bronchitis. - community-acquired pneumonia. - complicated skin and soft tissue infections

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - levofloxacin hemihydrate - film-coated tablet - 500 milligram(s) - fluoroquinolones; levofloxacin - quinolone antibacterials, fluoroquinolones - it is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): - acute bacterial sinusitis. - acute exacerbations of chronic bronchitis. - community-acquired pneumonia. - complicated skin and soft tissue infections

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 nosocomial pneumonia levofloxacin tablet is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)]. 1.2 community-acquired pneumonia: 7 to 14 day treatment regimen levofloxacin tablet is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcu

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 nosocomial pneumonia levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)]. 1.2 community-acquired pneumonia: 7 to 14 day treatment regimen levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 nosocomial pneumonia levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)]. 1.2 community-acquired pneumonia: 7 to 14 day treatment regimen levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 nosocomial pneumonia levofloxacin tablet is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)]. 1.2 community-acquired pneumonia: 7 to 14 day treatment regimen levofloxacin tablet is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcu